Aptus Pharma Board Approves 3:2 Bonus Share Issue, Plans ₹25 Cr Capital Increase

Aptus Pharma Limited's board of directors met on March 24, 2026, approving plans to boost the company's authorized share capital significantly and issue bonus shares. The board proposed increasing the authorized share capital from ₹7.15 crore to ₹25 crore. Alongside this, they recommended issuing bonus equity shares to existing shareholders in a 3:2 ratio.

Key Board Decisions

At a board meeting held on March 24, 2026, Aptus Pharma Limited's directors approved two key corporate actions.

Firstly, the board approved a substantial increase in the company's authorized share capital. This capital base will be expanded from the current ₹7.15 crore to a proposed ₹25.00 crore.

Secondly, a recommendation was made to issue bonus equity shares to existing shareholders. The proposed ratio is three new bonus shares for every two shares currently held.

Both of these proposals are subject to the approval of Aptus Pharma's members, who will cast their votes through a postal ballot and e-voting mechanism.

Why This Matters

A bonus issue serves as a direct reward to shareholders, increasing their shareholding without requiring additional investment. This can potentially boost share liquidity and make the stock more attractive to a wider investor base.

The significant enhancement of authorized share capital provides Aptus Pharma with greater financial flexibility. This allows the company to pursue future strategic opportunities, such as expansion projects, acquisitions, or other corporate actions, without immediate capital constraints.

The Backstory

Aptus Pharma Limited has not undertaken any major bonus share issues or significant increases in its authorized share capital in the preceding 24 months. The current proposals mark a strategic initiative to reward its investor base and prepare for anticipated future growth or corporate restructuring.

What Changes Now

• Shareholders may see their holdings increase significantly if the 3:2 bonus issue is approved.
• The company gains substantial flexibility for future capital-raising activities or strategic financial maneuvers.
• The total number of outstanding equity shares will rise post-bonus issue, affecting per-share metrics.
• The face value of ₹10 per share remains constant, but the overall equity base expands.

Risks to Watch

The primary short-term risk is the outcome of the members' vote. The proposed increase in authorized share capital and the bonus share issue are contingent on shareholder approval via postal ballot and e-voting. Any dissent could halt these plans.

Peer Comparison

Leading Indian pharmaceutical players like Divi's Laboratories Ltd., focused on API manufacturing, and global entities such as Lupin Ltd. and Aurobindo Pharma Ltd., also strong in APIs, often prioritize organic growth. Historically, major peers have been selective with bonus issues; Lupin Ltd. last issued bonus shares in 2018, while Aurobindo Pharma has not announced one in recent years. Aptus Pharma's proposal stands out as a proactive measure to enhance shareholder returns.

Key Metrics

• Proposed Authorized Share Capital: ₹25.00 crore (as of March 24, 2026)
• Current Authorized Share Capital: ₹7.15 crore (as of March 24, 2026)
• Bonus Share Ratio Recommended: 3:2 (three bonus shares for every two existing shares), face value ₹10 (as of March 24, 2026)

What to Track Next

• The formal appointment of a scrutinizer for the postal ballot and e-voting.
• The official announcement of the e-voting period duration and dates.
• The final outcome of the shareholder vote on both proposals.
• If approved, the determination and announcement of the bonus share record date.
• Future communication from Aptus Pharma on how the increased authorized capital will be utilized.